Abstract
Introduction
The renin-angiotensin system (RAS) has been demonstrated to play a critical role in the initiation of inflammation that contributes hypertension and cardiac remodeling [1] . Angiotensin II (Ang II) is a multi-functional hormone that has a major role in regulating blood pressure and cardiovascular homoeostasis via angiotensin II receptor type 1 (AT1R) or type 2 (AT2R) [1] . Accumulating evidence indicates that activated effector T lymphocytes exert a key role in the inflammatory response that has been described in cardiovascular disease, such as hypertension, atherosclerosis and heart failure [2] . Initially, The two effector Th subsets are Th1 and Th2. Th1 cells were positively associated with various cardiovascular diseases [3] . Currently, it has been demonstrated that many factors can regulate T cell differentiation toward the Th1 or the Th2 phenotype including T-box expressed in T cells (T-bet) and (GATA3) T-bet is a'master regulator'of Th1 cell development, while GATA3 is a key T-cell transcription factor to regulate Th2 T-cell differentiation [4] , Recently, Ang II-mediated signalling has been reported to play a critical role in Th differentiation [5] . However, the precise mechanism by which Ang II promotes Th1 differentiation remains to be defined.
The ubiquitin-proteasome system (UPS) plays a primary role in the protein quality control by removal of damaged, oxidized, and misfolded proteins [6] . The 26S proteasome constitutes major proteolytic machinery in the cell, which consists of a 20S core particle and a 19S regulatory particle (also known as PA700) [6] . The 20S core harbors the three catalytic subunits β1, β2 and β5 in the inner β-rings. These constitutive subunits can be replaced by the immune-proteasome subunits β1i (LMP2), β2i (MECL-1), and β5i (LMP7), respectively, in cells in response to pro-inflammatory cytokines such as IFN-γ [7] , resulting in the alteration of proteolytic activities of proteasome. It is known that β1/β1i, β2/β2i and β5/β5i are responsible for caspase-like, trypsin-like, and chymotrypsin-like activities, respectively [6] . Increasing evidence indicates that proteasome complex plays a major role in regulating cell cycle, differentiation and inflammatory response [6] . A well-known example of the ubiquitin-dependent regulation in the immune system is the proteasomedependent processing of peptides in antigen-presenting cells [8] . It is also reported that lipopolysaccharide (LPS) or pro-inflammatory cytokines such as IL-1 can induce activation of NF-κB through ubiquitination and subsequent degradation of the inhibitor of IκBα [8] .
Apart from its role in antigen presentation, immune-proteasomes shape the T cell repertoire and are responsible for the survival and expansion of T cells [9] . However, the requirement of proteasome activation in Ang II-induced Th cell differentiation has not been explored.
In the present study, we investigated the role of proteasome activation in Ang II-induced Th1/Th2 differentiation in T cells and the underlying mechanism. Our results for the first time demonstrated that Ang II significantly induced a shift from Th0 to Th1 cell differentiation through AT1R/PKA and proteasome activation, which caused both degradation of MKP-1 and IκBα and activation of STAT1 and NF-κB. Collectively, these data suggest that the direction of Th1/Th2 cell differentiation could be controlled by activation of proteasome during Ang II stimulation.
Materials and Methods

Antibodies and reagents
Anti-ubiquitin (Ub) was purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-β1, anti-β2, anti-β5, anti-β1i, anti-β2i and anti-β5i were obtained from BD Biosciences. Anti-MKP-1, anti-STAT1,antiphospho-STAT1(Ser727),anti-IκBα,anti-phospho-IκBα,anti-NF-κB/p65,anti-phospho-NF-κB/p65,anti-β-actin and horseradish peroxidase-conjugated goat anti-mouse and anti-rabbit IgG secondary antibody were purchased from Cell Signaling Technology (Beverly, MA). Angiotension II (Ang II) was purchased from Sigma-Aldrich (St Louis, MO, USA). Bortezomib (BTZ) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Trypsin, streptomycin, penicillin and fetal calf serum (FCS) were from Hyclone (Logan, UT, USA). Losartan (LST), U0126, wortmannin, SB203580, SP600125 and H-89 were supplied by Calbiochem (La 
Cell culture and treatment with inhibitors
Jurkat cells (Clone E6-1), a Th0-like human T lymphoblastoid cell line (ATCC), were grown in suspension at 37°C in 5% CO 2 , in RPMI 1640 medium supplemented with glutamine (2 mM), 10% fetal bovine serum, and penicillin (100 units/ml) and streptomycin (100 μg/ml) as described [10] . The cells were passed at a dilution of 1:15 once or twice a week to maintain the maximal density of 2-3 × 10 6 cells/ml. Primary human T cells (CD4 + T) were isolated from anonymous donor blood after apheresis by negative selection (STEMCELL Technologies #15062) as described previously [11] . T cells were cultured in suspension at 37°C in 5% CO 2 , RPMI 1640 medium consisting of glutamine (2 mM), 5% fetal bovine serum. All T cells were cultured for 1 to 2 days to maintain the maximal density of 1× 10 6 cells/ml. To evaluate the involvement of signaling pathways in Ang II-induced cell differentiation, cells were pretreated with BTZ (proteasome inhibitor, 10 μM), LST (AT1 receptor inhibitor, 10 μM), wortmannin (PI3K inhibitor, 200 nM), U0126 (MEK inhibitor, 10 μM), SB203580 (p38 MAPK inhibitor, 10 μM), SP600125 (JNK inhibitor, 10 μM) and H-89 (PKA inhibitor, 0.5 μM) for 30 min before exposure to Ang II (100 nM).
Quantitative real-time PCR analysis
Total RNA was extracted from cultured cells using TRIzol method (Invitrogen), and 2 μg RNA samples were reverse-transcribed to generate first-strand cDNA. Quantitative real-time PCR (qPCR) analysis was performed as described previously [12] . The primer sequences of IFNγ, IL-2, IL-4, IL-10, T-bet, IFN-γ, GATA and GAPDH were described as the following: IL-2: 
ELISA assay of IFNγ and IL-2 protein levels
The enzyme-linked immunosorbent assay (ELISA) was performed as described previously [8] . The protein levels of IFNγ and IL-2 were measured with an enzyme-linked immunosorbent assay (ELISA) according to the manufacturer's instructions (CUSABIO, America). Briefly, samples and standards were incubated for 2 hours at 37°C. The biotin-labeled anti-IFNγ or IL-2 antibody was used for detection in a 1:100 dilution and incubated for 1 hour at 37°C. 3, 3', 5, 5-tetramethylbenzidine (TMB) substrate was added to each well after labeling with HRP-avidin for 1 hour at 37°C, and incubated in the dark for 15-30 minutes at 37°C. Microtiter plates were read at 450 nm within 5 minutes after adding stop solution to each well.
Assay for proteasome activity
The 26S proteasome activity was analyzed based on a previously published method [13] . Briefly, cells were harvested and lysed with proteasome lysis buffer (50 mM Tris-HCl, pH 7.8, 20 mM KCl, 5 mM MgCl 2 , 1 mM DTT, 1 mM ATP, 10% glycerol, and 0.04% Nonidet P-40), followed by incubation on ice for 20 min. Cell lysate with 10-30 μg of proteins was incubated with HEPES buffer containing the fluorogenic substrates and incubated at 37°C for 1 h. The caspase-like activity was determined with Z-LLE-AMC (45 μM), trypsin-like activity with Ac-RLR-AMC (40 μM), and chymotrypsin-like activity with Suc-LLVY-AMC (18 μM) as substrates in the absence or presence of a proteasome inhibitor, MG-132 (20 μM) for chymotrypsinlike and caspaselike activities, or epoxomycin (5 μM) for trypsin-like activity. The fluorescence intensity was measured with the excitation at 380 nm and emission at 460 nm.
Western blot analysis
Western blot analysis was performed as previously described [8] . Cells were lysed with lysis buffer (20 mM Tris (pH7.5), 1 mM EDTA, 150 mM NaCl, 1 mM EGTA, 1 mM β-glycerophosphate, 1%Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM Na3VO4, 4 µg/ml aprotinin, 4 µg/ml leupeptin, 4 µg/ml pepstatin, and 1 mM PMSF). No phosphatase inhibitors were included in the lysis buffer. 50-60 μg protein from each sample Cellular Physiology and Biochemistry
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were separated by SDS-PAGE, transferred to nitrocellulose membranes, and probed with primary antibodies against β1 (1:500), β2 (1:500), β5 (1:500), β1i (1:500), β2i (1:500), β5i (1:500), total-and phospho-STAT1 (1:1000), total-and phospho-IκBα (1:1000), total-and phospho-NF-κB/p65 (1:1000) and conjugated with horseradish peroxidase-conjugated secondary antibodies, For the phospho-specific protein, we normalized the signal to the amount of total target protein and β-actin.
Analysis of poly-ubiquitinated proteins
Cells were lysed with lysis buffer as above, Jurkat cells were treated with 100 nM of Ang II for different time points (0, 4, 8 and 24 h), and were further lysed with lysis buffer as above. Poly-ubiquitinated proteins were detected by Western blot analysis as described previously [8] . Briefly, 60 μg proteins from each time point were separated by SDS-PAGE and probed with primary antibodies against Ub (1:1000) and β-actin.
Statistical analysis
Data are expressed as mean±SEM. One-way ANOVA followed by Least-Significant-Difference test was conducted to compare three or more groups using SPSS version 12.0 (SPSS Inc., Chicago, IL). P< 0.05 was considered statistically significant.
Results
Ang II predominantly induces Th1 differentiation through AT1 receptor
To determine the causative role of Ang II in regulating T lymphocyte differentiation, we measured the expression of Th1 markers (IFN-γ and IL-2) and Th2 markers (IL-4 and IL-10) in Jurkat cells and normal primary human T cells (CD4 + T). qPCR analysis revealed that the expression levels of IL-2, IFN-γ, Il-4 and IL10 were similar, indicating that both Jurkat cells and primary human T cells are Th0 cells (Fig. 1A and 1B) . Moreover, treatment with Ang II (100 nM) significantly up-regulated the expression of IFN-γ (10-fold) and IL-2 (18-fold) but slightly increased the expression of IL-4 (3.5-fold) and IL-10 (1.5-fold) compared with control (Fig. 1C) . Since T-bet and GATA3 are the key regulators for Th1 and Th2 cell differentiation, respectively [4] , we then detected the expression levels of T-bet and GATA3 mRNA in Jurkat cells. After Ang II treatment, the expression of T-bet mRNA was markedly increased by 38-fold, whereas the expression of GATA3 mRNA was only increased by 1.6-fold as compared with control ( Fig. 1D-E) .
Previous study indicates that T lymphocytes mainly express AT1R and produce Ang II [14] , we then examined whether AT1R participates in the Th1 differentiation. Jurkat cells were pretreated with AT1R blocker losartan 
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(LST) for 30 min and then stimulated with Ang II for 24 h. As shown in Fig. 1C -E, LST completely abolished Ang II-induced expression of IFN-γ, IL-2 and T-bet (markers for Th1 differentiation), whereas LST had no significant effect on IL-4, IL-10 and GATA3 (markers for Th2 differentiation). Together, these data suggest that Ang II preferentially stimulates Th1 rather than Th2 differentiation via AT1R.
Ang II increases proteasome activities but reduces the pool of poly-ubiquitinated proteins
To determine the role of the proteasome in T lymphocyte differentiation, we first examined the effect of Ang II on proteasome activation. Jurkat cells were treated with Ang II at different doses (25, 50 and 100 nM) and at different time points (4, 8 and 24 h). The proteasome activities, including caspase-like, trypsin-like, and chymotrypsin-like activities were measured using fluorescent-labeled peptides. As shown in Fig. 2A , Ang II treatment markedly increased proteasome caspase-like, trypsin-like and chymotrypsin-like activities in a dose-dependent manner. Ang II also enhanced proteasome activities in a time-dependent manner (Fig. 2B) . Moreover, this induction was markedly attenuated by a specific proteasome inhibitor bortezomib (BTZ) (Fig. 2C) . These results suggest that Ang II-induced activities were specifically associated with the proteasome.
Ang II induces the expression of proteasome protein subunits
Proteasome activation has been known to increase the degradation of poly-ubiquitinated proteins. We next examined the levels of poly-ubiquitinated proteins by Western blot analysis in Jurkat cells. Ang II treatment for 0-24 h markedly decreased the levels of polyubiquitinated proteins in a time-dependent manner ( Fig. 3A and 3B ), indicating that Ang II can enhance the turnover of ubiquitinated proteins in Jurkat cells.
To determine the effect of Ang II in the expression of catalytic subunits, we treated Jurkat cells with Ang II (100 nM) at different time points (4, 8 and 24 h ). The protein levels of the constitutive and inducible proteasome catalytic subunits (including β1, β2, β5, β1i, β2i and β5i) were detected by Western blot analysis. Ang II treatment significantly increased the protein levels of constitutive subunit (β1) and immuno-subunits (β1i, β2i and β5i) but did not affect other constitutive subunits (β2 and β5) (Fig. 3C and D) , indicating that Ang II-induced increase of proteasome activity is mainly mediated by incread expression of proteasome subunits β1/β1i, β2i and β5i in Jurkat cells.
Ang II stimulates proteasome activation through AT1R-PKA signaling pathway
To further elucidate the signalling pathway whereby Ang II-induced proteasome activation, Jurkat cells were pretreated with different signalling inhibitors, including losartan 
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(LST, an AT1R inhibitor), H-89 (a PKA-specific inhibitor), wortmannin (a PI3K inhibitor), U0126 (a MEK inhibitor), SB203580 (a p38 MAPK inhibitor) and SP600125 (a JNK inhibitor).
As shown in Fig. 4A -F, Ang II-induced increase in proteasome activities (including caspaselike, trypsin-Like and chymotrypsin-like activities) were markedly attenuated by LST or H-89, respectively. In contrast, other inhibitors, including wortmannin, U0126, SB203580 and SP600125 had no effect. These results indicate that AT1R-PKA signalling pathway mediates Ang II-induced activation of the proteasome.
Proteasome inhibitor bortezomib suppresses Ang II-induced Th1 differentiation
To further determine whether proteasome activation mediates Ang II-induced Th1 differentiation, primary human T cells were pretreated with proteasome inhibitor bortezomib (BTZ) for 30 min and then stimulated with Ang II for additional 24 h. Ang II treatment resulted in a significant increase in the expressions of Th1 markers (IFN-γ, IL-2) but not Th2 markers (IL4, IL10) (Fig. 5A ). Also, we tested the effect of Ang II on Th1 markers and Th2 markers in Jurkat cells and we further treated the Jurkat cells with BTZ. Consistent with the findings observed in primary human T cells, Ang II-stimulated upregulation of Th1 markers (IFN-γ, IL-2 and T-bet) but not Th2 markers (IL4, IL10 and GATA3). BTZ treatment markedly attenuated Ang II-induced activities, suggesting Ang II were specifically associated with the proteasome (Fig. 5B-D) .
Bortezomib inhibits Ang II-induced the degradation of MKP-1 and IκBα and activation of STAT1 and NF-κB
It is well documented that STAT1 and NF-κB signalling pathways play critical roles in Th1 differentiation and activation [15] . MKP-1 and IκBα can negatively regulate activation of STAT1 and NF-κB, respectively, which are reported to be degradated by the proteasome [16] . To determine whether inhibition of proteasome reversed MKP-1 and IκBα protein 6A) . Importantly, BTZ treatment markedly reversed these effects. These data suggest that Ang II promotes STAT1 and NF-κB activation via enhancing degradation of MKP-1 and IκBα by the proteasome.
Discussion
In this study, we explored the role of proteasome activation in Ang II-induced T cell differentiation in Jurkat cells and primary human T cells. The present study demonstrated that Ang II induces the expression of proteasome protein subunits and predominantly stimulates Th1 differentiation. This effect of Ang II in proteasome activities is associated with activation of AT1R/PKA signaling pathway, which in turn promote the degradation of MKP-1 and IκBα and activation of STAT1 and NF-κB pathways that eventually lead to Th1 cell differentiation. Also, inhibition of proteasome activation or AT1R markedly attenuated these effects (Fig. 6B) . Hence this study uncovered new potential mechanisms exhibiting regulatory effect of UPS in Ang II induced Th1 cell differentiation.
The UPS is the main mechanism of ubiquitin-dependent degradation of intracellular proteins involved in the regulation of cell cycle, apoptosis, signal transduction and antigen presentation [17] . Importantly, many studies have demonstrated that proteasome activation plays a critical role in the development of various cardiovascular diseases [18] . Now it is known that the functions and activities of the 26S proteasome are regulated by multiple mechanisms. For example, post-translational modifications including phosphorylation and glycosylation have been reported to regulate the proteasome activities [17] . Recently, several factors, including reactive oxygen species (ROS), mechanical stress, and isoproterenol, were reported to promote catalytic subunit expression to generate immunoproteasomes, which have altered enzymatic activities for their substrates [17] . Ang II is known to bind its receptors to activate several signalling pathways, including MAPKs (ERK, JNK and p38 MAPK), PI3K/AKT, and PKA, which play important roles in mediating Ang II-induced cellular responses, such as cell growth, differentiation, reorganization of the cytoskeleton, and activation of a variety of protein kinases [1] . In this study, our data indicate that Ang II also enhanced proteasome activation (Fig. 2-4) , and this effect was completely blocked AT1R or PKA inhibitor (Fig. 4) . Hence, AT1R/PKA pathway is involved in Ang II-induced activation of the proteasome in T cells. Naive CD4 + T cells can differentiate into different Th cell lineages that are essential for efficient immune responses against different types of pathogens [4, 10] . Many factors are known to regulate Th1 and Th2 differentiation, especially renin-angiotensin system (RAS). A growing body of evidence suggests that anti-CD3/CD28 treatment also induces Th1 differentiation reflected by upregulation of IL-2, IFN-α and NF-kB activity in Jurkat cells or in human CD4
+ T cells [19, 20] . Many factors are known to regulate Th1 and Th2 differentiation, including renin-angiotensin system (RAS).Ang II, a major effector of RAS, plays a critical role in this process. For example, splenocytes from high Ang II-treated Apo E knockout mice produce elevated levels of IFN-γ (a marker for Th1 cells) and decreased levels of IL4 and IL10 (markers for Th2 cells), and this effect was blocked by pretreatment with AT1R blocker olmesartan [21] . Co-stimulation of T cells via B7 ligands was found essential for the development of Ang II-induced hypertension [22] . Moreover, Ang II can enhance Th1 cell activation that speeds up atherogenesis [23] . In addition to the classic circulating RAS, all RAS components have been identified in the heart, which may mediate autocrine, paracrine, and intracrine effects [24] . Interestingly, endogenous Ang II production is increased in the ischemic and hypertrophic myocardium or in the 2K1C hypertension model in ApoE −/− mice, and participate in cardiovascular events including atherosclerosis [23, 25] . Endogenous Ang II induces atherosclerotic plaque vulnerability and elicits a Th1 response in ApoE −/− mice, suggesting Ang II plays a critical role in regulating Th1 differentiation [23] . In this study, Ang II stimulates Th1 differentiation via enhancing proteasome activity and proteasome inhibitor bortezomib significantly inhibited Ang II-induced Th1 differentiation (Fig. 5) .
Recently, several transcription factors that control Th1/Th2 cell differentiation were identified [26, 27] . Of these, T-bet and GATA3 are found to be the key regulators for Th1 and Th2 cell differentiation [28] . Yang et al. reported that STAT1/4 can bind T-bet enhancer and regulate T-bet expression [15] . Also, MKP-1 is a dual specificity nuclear phosphatase responsible for dephosphorylation at both serine/threonine and tyrosine residues and is involved in the dephosphorylation of IFNγ-activated nuclear STAT1 [16, 29] .Interestingly, MKP-1 is also involved in dephosphorylation of STAT1 induced by Ang II, but not in the inactivation of STAT3 activated by IL-6 [24] . Furthermore, NF-κB is regulated by the inhibitor protein IκBα, which retains NF-κB in the cytoplasm [30] . Importantly, both MKP-1 and IκBα protein levels were regulated by ubiquitin-mediated proteasomal degradation [16] . The present results demonstrated that Ang II markedly promoted Th1 cell differentiation, and down-regulated protein levels of MKP-1 and IκBα resulting in activation of STAT1 and NF-κB pathways. Importantly, inhibition of proteasome by BTZ markedly reversed these effects (Fig.  6A) , suggesting Ang II stimulates Th1 cell differentiation via activation of the proteasome in Jurkat cells.
Conclusion
Our study demonstrates for the first time that Ang II activates AT1R/PKA signalling pathway, which in turn to increase the catalytic subunit expression and activity of proteasome,
